CH573435A5 - - Google Patents

Info

Publication number
CH573435A5
CH573435A5 CH955873A CH955873A CH573435A5 CH 573435 A5 CH573435 A5 CH 573435A5 CH 955873 A CH955873 A CH 955873A CH 955873 A CH955873 A CH 955873A CH 573435 A5 CH573435 A5 CH 573435A5
Authority
CH
Switzerland
Application number
CH955873A
Original Assignee
Takeda Chemical Industries Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Takeda Chemical Industries Ltd filed Critical Takeda Chemical Industries Ltd
Publication of CH573435A5 publication Critical patent/CH573435A5/xx

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D499/00Heterocyclic compounds containing 4-thia-1-azabicyclo [3.2.0] heptane ring systems, i.e. compounds containing a ring system of the formula:, e.g. penicillins, penems; Such ring systems being further condensed, e.g. 2,3-condensed with an oxygen-, nitrogen- or sulfur-containing hetero ring

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
CH955873A 1972-07-01 1973-06-29 CH573435A5 (enExample)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
JP6630172A JPS5512435B2 (enExample) 1972-07-01 1972-07-01

Publications (1)

Publication Number Publication Date
CH573435A5 true CH573435A5 (enExample) 1976-03-15

Family

ID=13311838

Family Applications (1)

Application Number Title Priority Date Filing Date
CH955873A CH573435A5 (enExample) 1972-07-01 1973-06-29

Country Status (15)

Country Link
US (1) US3925357A (enExample)
JP (1) JPS5512435B2 (enExample)
AT (1) AT325206B (enExample)
AU (1) AU469986B2 (enExample)
BE (1) BE801588A (enExample)
CA (1) CA996548A (enExample)
CH (1) CH573435A5 (enExample)
CS (1) CS168036B2 (enExample)
DE (1) DE2332840A1 (enExample)
FR (1) FR2190414B1 (enExample)
GB (1) GB1386566A (enExample)
HU (1) HU166029B (enExample)
NL (1) NL7308048A (enExample)
PL (1) PL92969B1 (enExample)
SE (1) SE402916B (enExample)

Families Citing this family (31)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS5522148U (enExample) * 1978-07-29 1980-02-13
PT1757606E (pt) * 2001-02-24 2009-05-26 Boehringer Ingelheim Pharma Utilização de derivados de xantina como produto farmacêutico, bem como seu processo de preparação
US20030171424A1 (en) * 2002-03-07 2003-09-11 Lin Ai J. Intravenous formulation of artelinic acid for treatment of severe and complicated malaria
US7407955B2 (en) 2002-08-21 2008-08-05 Boehringer Ingelheim Pharma Gmbh & Co., Kg 8-[3-amino-piperidin-1-yl]-xanthines, the preparation thereof and their use as pharmaceutical compositions
US7501426B2 (en) * 2004-02-18 2009-03-10 Boehringer Ingelheim International Gmbh 8-[3-amino-piperidin-1-yl]-xanthines, their preparation and their use as pharmaceutical compositions
DE102004054054A1 (de) * 2004-11-05 2006-05-11 Boehringer Ingelheim Pharma Gmbh & Co. Kg Verfahren zur Herstellung chiraler 8-(3-Amino-piperidin-1-yl)-xanthine
DE102005035891A1 (de) 2005-07-30 2007-02-08 Boehringer Ingelheim Pharma Gmbh & Co. Kg 8-(3-Amino-piperidin-1-yl)-xanthine, deren Herstellung und deren Verwendung als Arzneimittel
PE20080251A1 (es) * 2006-05-04 2008-04-25 Boehringer Ingelheim Int Usos de inhibidores de dpp iv
EP1852108A1 (en) * 2006-05-04 2007-11-07 Boehringer Ingelheim Pharma GmbH & Co.KG DPP IV inhibitor formulations
NZ619413A (en) 2006-05-04 2015-08-28 Boehringer Ingelheim Int Polymorphs of a dpp-iv enzyme inhibitor
US20110112069A1 (en) * 2007-08-17 2011-05-12 Boehringer Ingelheim International Gmbh Purin derivatives for use in the treatment of fab-related diseases
PE20140960A1 (es) 2008-04-03 2014-08-15 Boehringer Ingelheim Int Formulaciones que comprenden un inhibidor de dpp4
PE20100156A1 (es) * 2008-06-03 2010-02-23 Boehringer Ingelheim Int Tratamiento de nafld
UY32030A (es) 2008-08-06 2010-03-26 Boehringer Ingelheim Int "tratamiento para diabetes en pacientes inapropiados para terapia con metformina"
KR20190016601A (ko) 2008-08-06 2019-02-18 베링거 인겔하임 인터내셔날 게엠베하 메트포르민 요법이 부적합한 환자에서의 당뇨병 치료
KR101791403B1 (ko) * 2008-08-15 2017-10-30 베링거 인겔하임 인터내셔날 게엠베하 Fab-관련 질환의 치료에 사용하기 위한 퓨린 유도체
AU2009290911A1 (en) 2008-09-10 2010-03-18 Boehringer Ingelheim International Gmbh Combination therapy for the treatment of diabetes and related conditions
US20200155558A1 (en) 2018-11-20 2020-05-21 Boehringer Ingelheim International Gmbh Treatment for diabetes in patients with insufficient glycemic control despite therapy with an oral antidiabetic drug
JP2012512848A (ja) 2008-12-23 2012-06-07 ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング 有機化合物の塩の形態
TW201036975A (en) 2009-01-07 2010-10-16 Boehringer Ingelheim Int Treatment for diabetes in patients with inadequate glycemic control despite metformin therapy
MX364651B (es) 2009-11-27 2019-05-03 Boehringer Ingelheim Int Gmbh Star Inhibidores de dpp-iv, tales como la linagliptina, y composiciones farmacéuticas o combinaciones que comprenden los mismos, para usarse en el tratamiento de pacientes diabéticos tipificados genéticamente.
ES2935300T3 (es) 2010-05-05 2023-03-03 Boehringer Ingelheim Int Combiterapia
KR20190050871A (ko) 2010-06-24 2019-05-13 베링거 인겔하임 인터내셔날 게엠베하 당뇨병 요법
AR083878A1 (es) 2010-11-15 2013-03-27 Boehringer Ingelheim Int Terapia antidiabetica vasoprotectora y cardioprotectora, linagliptina, metodo de tratamiento
DK3517539T3 (en) 2011-07-15 2023-01-16 Boehringer Ingelheim Int Farmaceutiske sammensætninger til behandling af type i og type ii diabetes
US9555001B2 (en) 2012-03-07 2017-01-31 Boehringer Ingelheim International Gmbh Pharmaceutical composition and uses thereof
EP3685839A1 (en) 2012-05-14 2020-07-29 Boehringer Ingelheim International GmbH Linagliptin for use in the treatment of albuminuria and kidney related diseases
ES2929025T3 (es) 2012-05-14 2022-11-24 Boehringer Ingelheim Int Linagliptina, un derivado de xantina como inhibidor de dpp-4, para su uso en el tratamiento del SRIS y/o de la septicemia
WO2013174767A1 (en) 2012-05-24 2013-11-28 Boehringer Ingelheim International Gmbh A xanthine derivative as dpp -4 inhibitor for use in modifying food intake and regulating food preference
JP6615109B2 (ja) 2014-02-28 2019-12-04 ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング Dpp−4阻害薬の医学的使用
CN109310697A (zh) 2016-06-10 2019-02-05 勃林格殷格翰国际有限公司 利格列汀和二甲双胍的组合

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR1026793A (fr) * 1949-08-02 1953-05-04 American Cyanamid Co Procédé de préparation de sels de pénicilline
NL6803062A (enExample) * 1967-03-10 1968-09-11
US3557094A (en) * 1968-01-05 1971-01-19 Pfizer & Co C Substituted alkyl esters of alpha-carboxy aryl penicillins
AT290728B (de) * 1968-09-28 1971-05-15 Takeda Chemical Industries Ltd Verfahren zur herstellung neuer penicilline

Also Published As

Publication number Publication date
PL92969B1 (enExample) 1977-04-30
DE2332840A1 (de) 1974-01-17
FR2190414A1 (enExample) 1974-02-01
JPS4925121A (enExample) 1974-03-06
BE801588A (fr) 1973-12-28
AT325206B (de) 1975-10-10
NL7308048A (enExample) 1974-01-03
HU166029B (enExample) 1974-12-28
JPS5512435B2 (enExample) 1980-04-02
CS168036B2 (enExample) 1976-05-28
AU469986B2 (en) 1976-02-26
SE402916B (sv) 1978-07-24
FR2190414B1 (enExample) 1976-07-02
GB1386566A (en) 1975-03-12
AU5760073A (en) 1975-01-09
CA996548A (en) 1976-09-07
US3925357A (en) 1975-12-09

Similar Documents

Publication Publication Date Title
FR2190414B1 (enExample)
JPS499971U (enExample)
JPS4957116A (enExample)
FR2175004B3 (enExample)
JPS5131913Y2 (enExample)
JPS5437326B2 (enExample)
JPS4898787A (enExample)
JPS5517367Y2 (enExample)
JPS5619988Y2 (enExample)
CS152245B1 (enExample)
JPS497153A (enExample)
CH588812A5 (enExample)
CH569984A5 (enExample)
BG20750A3 (enExample)
BG20736A1 (enExample)
CH605668A5 (enExample)
CH601027A5 (enExample)
CH592915B5 (enExample)
BG18288A1 (enExample)
CH577532A5 (enExample)
CH576134B5 (enExample)
CH574115A5 (enExample)
CH572184A5 (enExample)
CH572094A5 (enExample)
CH571736B5 (enExample)

Legal Events

Date Code Title Description
PL Patent ceased
PL Patent ceased